Inhibikase Historical Balance Sheet

IKT Stock

USD 2.72 0.04 1.45%

Trend analysis of Inhibikase Therapeutics balance sheet accounts such as Accounts Payable of 1 M or Other Assets of 1.09 provides information on Inhibikase Therapeutics' total assets, liabilities, and equity, which is the actual value of Inhibikase Therapeutics to its prevalent stockholders. By breaking down trends over time using Inhibikase Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Inhibikase Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inhibikase Therapeutics is a good buy for the upcoming year.

Inhibikase Therapeutics Inventory

858,818

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.

About Inhibikase Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Inhibikase Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Inhibikase Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Inhibikase Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Inhibikase currently owns. An asset can also be divided into two categories, current and non-current.

Inhibikase Therapeutics Balance Sheet Chart

At this time, Inhibikase Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Total Liabilities is likely to gain to about 3.3 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.

Total Current Liabilities Accounts Payable Other Assets Total Current Assets Current Deferred Revenue Non Currrent Assets Other

Total Current Liabilities

Total Current Liabilities is an item on Inhibikase Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Inhibikase Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Inhibikase Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Inhibikase Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most accounts from Inhibikase Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Inhibikase Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.At this time, Inhibikase Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Total Liabilities is likely to gain to about 3.3 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.

	2022	2024	2025 (projected)
Other Assets	1.0	1.15	1.09
Accounts Payable	1.2M	743.8K	1.0M

Other Assets Accounts Payable

Inhibikase Therapeutics balance sheet Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Total Current Assets	Common Stock	Other Current Liab	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Net Invested Capital
Total Current Liabilities		0.62	-0.62	0.9	0.42	-0.02	0.65	0.35	0.83	0.61	0.54	0.59	0.85	-0.55	0.58	-0.9	0.71	0.65	-0.75	0.55	-0.52	0.43	0.63	0.47	-0.89	0.59
Net Tangible Assets	0.62		-0.95	0.44	0.06	-0.24	0.81	0.51	0.79	0.82	0.7	0.82	0.83	-0.61	0.68	-0.71	0.87	0.83	-0.93	0.89	-0.43	0.65	0.95	-0.21	-0.79	0.82
Retained Earnings	-0.62	-0.95		-0.38	0.12	0.27	-0.63	-0.29	-0.78	-0.63	-0.85	-0.63	-0.82	0.4	-0.47	0.71	-0.82	-0.65	0.87	-0.95	0.64	-0.51	-0.93	0.24	0.8	-0.63
Accounts Payable	0.9	0.44	-0.38		0.49	-0.06	0.6	0.45	0.59	0.57	0.23	0.54	0.71	-0.53	0.55	-0.78	0.63	0.6	-0.68	0.27	-0.41	0.31	0.41	0.68	-0.75	0.54
Other Assets	0.42	0.06	0.12	0.49		0.63	0.45	0.34	0.38	0.43	-0.26	0.43	0.15	-0.61	0.57	-0.18	0.2	0.42	-0.16	-0.13	0.47	0.47	0.06	0.33	-0.09	0.43
Net Receivables	-0.02	-0.24	0.27	-0.06	0.63		-0.15	-0.08	0.13	-0.15	-0.3	-0.14	-0.36	0.1	-0.12	0.4	-0.28	-0.17	0.31	-0.26	0.38	-0.07	-0.25	-0.21	0.4	-0.14
Total Current Assets	0.65	0.81	-0.63	0.6	0.45	-0.15		0.79	0.73	0.99	0.34	0.99	0.81	-0.92	0.93	-0.72	0.85	1.0	-0.85	0.62	-0.02	0.76	0.81	0.19	-0.74	0.99
Common Stock	0.35	0.51	-0.29	0.45	0.34	-0.08	0.79		0.46	0.81	-0.14	0.81	0.44	-0.68	0.67	-0.38	0.47	0.8	-0.5	0.23	0.18	0.29	0.45	0.19	-0.43	0.82
Other Current Liab	0.83	0.79	-0.78	0.59	0.38	0.13	0.73	0.46		0.7	0.64	0.7	0.79	-0.57	0.6	-0.75	0.71	0.72	-0.73	0.77	-0.37	0.49	0.82	0.01	-0.8	0.7
Total Assets	0.61	0.82	-0.63	0.57	0.43	-0.15	0.99	0.81	0.7		0.3	1.0	0.77	-0.92	0.94	-0.69	0.83	1.0	-0.84	0.6	0.01	0.76	0.8	0.13	-0.71	1.0
Short Long Term Debt Total	0.54	0.7	-0.85	0.23	-0.26	-0.3	0.34	-0.14	0.64	0.3		0.3	0.74	-0.15	0.21	-0.63	0.68	0.33	-0.66	0.91	-0.72	0.41	0.79	-0.21	-0.69	0.29
Total Stockholder Equity	0.59	0.82	-0.63	0.54	0.43	-0.14	0.99	0.81	0.7	1.0	0.3		0.76	-0.92	0.93	-0.67	0.82	1.0	-0.83	0.6	0.03	0.76	0.8	0.1	-0.69	1.0
Current Deferred Revenue	0.85	0.83	-0.82	0.71	0.15	-0.36	0.81	0.44	0.79	0.77	0.74	0.76		-0.65	0.68	-0.93	0.94	0.8	-0.93	0.82	-0.54	0.6	0.89	0.29	-0.95	0.76
Net Debt	-0.55	-0.61	0.4	-0.53	-0.61	0.1	-0.92	-0.68	-0.57	-0.92	-0.15	-0.92	-0.65		-0.99	0.64	-0.68	-0.92	0.68	-0.38	-0.24	-0.85	-0.61	-0.28	0.59	-0.92
Cash	0.58	0.68	-0.47	0.55	0.57	-0.12	0.93	0.67	0.6	0.94	0.21	0.93	0.68	-0.99		-0.68	0.71	0.94	-0.73	0.43	0.17	0.87	0.65	0.22	-0.64	0.93
Non Current Assets Total	-0.9	-0.71	0.71	-0.78	-0.18	0.4	-0.72	-0.38	-0.75	-0.69	-0.63	-0.67	-0.93	0.64	-0.68		-0.77	-0.73	0.82	-0.64	0.53	-0.53	-0.72	-0.45	0.98	-0.67
Non Currrent Assets Other	0.71	0.87	-0.82	0.63	0.2	-0.28	0.85	0.47	0.71	0.83	0.68	0.82	0.94	-0.68	0.71	-0.77		0.84	-0.97	0.83	-0.43	0.71	0.92	0.13	-0.82	0.82
Cash And Short Term Investments	0.65	0.83	-0.65	0.6	0.42	-0.17	1.0	0.8	0.72	1.0	0.33	1.0	0.8	-0.92	0.94	-0.73	0.84		-0.86	0.61	-0.03	0.76	0.81	0.16	-0.75	1.0
Common Stock Total Equity	-0.75	-0.93	0.87	-0.68	-0.16	0.31	-0.85	-0.5	-0.73	-0.84	-0.66	-0.83	-0.93	0.68	-0.73	0.82	-0.97	-0.86		-0.8	0.49	-0.68	-0.9	-0.12	0.88	-0.83
Common Stock Shares Outstanding	0.55	0.89	-0.95	0.27	-0.13	-0.26	0.62	0.23	0.77	0.6	0.91	0.6	0.82	-0.38	0.43	-0.64	0.83	0.61	-0.8		-0.57	0.53	0.96	-0.27	-0.73	0.59
Non Current Liabilities Total	-0.52	-0.43	0.64	-0.41	0.47	0.38	-0.02	0.18	-0.37	0.01	-0.72	0.03	-0.54	-0.24	0.17	0.53	-0.43	-0.03	0.49	-0.57		0.14	-0.43	-0.08	0.61	0.03
Other Current Assets	0.43	0.65	-0.51	0.31	0.47	-0.07	0.76	0.29	0.49	0.76	0.41	0.76	0.6	-0.85	0.87	-0.53	0.71	0.76	-0.68	0.53	0.14		0.67	-0.05	-0.48	0.76
Other Stockholder Equity	0.63	0.95	-0.93	0.41	0.06	-0.25	0.81	0.45	0.82	0.8	0.79	0.8	0.89	-0.61	0.65	-0.72	0.92	0.81	-0.9	0.96	-0.43	0.67		-0.15	-0.8	0.79
Total Liab	0.47	-0.21	0.24	0.68	0.33	-0.21	0.19	0.19	0.01	0.13	-0.21	0.1	0.29	-0.28	0.22	-0.45	0.13	0.16	-0.12	-0.27	-0.08	-0.05	-0.15		-0.34	0.11
Deferred Long Term Liab	-0.89	-0.79	0.8	-0.75	-0.09	0.4	-0.74	-0.43	-0.8	-0.71	-0.69	-0.69	-0.95	0.59	-0.64	0.98	-0.82	-0.75	0.88	-0.73	0.61	-0.48	-0.8	-0.34		-0.69
Net Invested Capital	0.59	0.82	-0.63	0.54	0.43	-0.14	0.99	0.82	0.7	1.0	0.29	1.0	0.76	-0.92	0.93	-0.67	0.82	1.0	-0.83	0.59	0.03	0.76	0.79	0.11	-0.69

Click cells to compare fundamentals

Inhibikase Therapeutics Account Relationship Matchups

Inhibikase Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	4.7M	4.1M	3.7M	3.4M	4.0M	3.7M
Net Tangible Assets	(778.0K)	(4.5M)	9.8M	38.4M	44.2M	46.4M
Retained Earnings	(15.0M)	(29.8M)	(47.9M)	(66.9M)	(60.2M)	(57.2M)
Accounts Payable	1.7M	1.1M	1.2M	646.8K	743.8K	1.0M
Other Assets	2.9K	829.2K	1.6M	1.0	1.15	1.09
Total Current Assets	14.8M	42.5M	24.4M	14.2M	16.3M	13.4M
Common Stock	10.1K	25.2K	25.2K	6.2K	7.1K	13.9K
Other Current Liab	632.9K	2.7M	2.4M	2.3M	2.6M	1.9M
Total Assets	14.8M	42.5M	24.9M	14.5M	16.7M	18.3M
Short Long Term Debt Total	319.0K	248.9K	351.3K	622.0K	715.3K	393.9K
Total Stockholder Equity	9.8M	38.4M	21.0M	11.0M	12.6M	13.7M
Net Debt	(13.6M)	(40.5M)	(6.8M)	(8.5M)	(7.7M)	(8.1M)
Cash	14.0M	40.8M	7.2M	9.2M	10.5M	13.1M
Cash And Short Term Investments	14.0M	40.8M	23.1M	13.3M	15.2M	16.8M
Common Stock Shares Outstanding	1.7M	3.0M	4.2M	5.3M	6.1M	3.2M
Liabilities And Stockholders Equity	14.8M	42.5M	24.9M	14.5M	16.7M	18.3M
Non Current Liabilities Total	276.5K	2.7M	205.5K	90.1K	81.1K	77.1K
Other Current Assets	829.2K	1.6M	163.5K	959.0K	1.1M	729.2K
Other Stockholder Equity	24.8M	68.2M	68.8M	77.9M	89.6M	46.4M
Total Liab	5.0M	4.1M	3.9M	3.5M	3.2M	3.3M
Net Invested Capital	10.1M	38.7M	21.0M	11.0M	12.6M	14.0M
Capital Stock	10.1K	25.2K	25.2K	6.2K	7.1K	6.8K
Net Working Capital	10.1M	38.4M	20.7M	10.8M	12.4M	13.4M
Short Term Debt	42.5K	248.9K	145.8K	531.9K	611.7K	642.2K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Inhibikase Stock Analysis

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inhibikase Historical Balance Sheet

Inhibikase Therapeutics Inventory

858,818

About Inhibikase Balance Sheet Analysis

Inhibikase Therapeutics Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Total Current Assets

Current Deferred Revenue

Non Currrent Assets Other

Inhibikase Therapeutics balance sheet Correlations

Inhibikase Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inhibikase Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Inhibikase Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Current Assets
Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity

Cash	- 0.99	Net Debt
Common Stock Total Equity	- 0.97	Non Currrent Assets Other
Deferred Long Term Liab	- 0.95	Current Deferred Revenue
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Net Tangible Assets
Common Stock Total Equity	- 0.93	Current Deferred Revenue